0.1489
3.47%
+0.0049
Zomedica Corp stock is currently priced at $0.1489, with a 24-hour trading volume of 4.16M.
It has seen a +3.47% increased in the last 24 hours and a +9.24% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.1428 pivot point. If it approaches the $0.1528 resistance level, significant changes may occur.
Zomedica Corp Stock (ZOM) Financials Data
Zomedica Corp (ZOM) Revenue 2023
ZOM reported a revenue (TTM) of $24.01 million for the quarter ending September 30, 2023, a +42.44% rise year-over-year.
Zomedica Corp (ZOM) Net Income 2023
ZOM net income (TTM) was -$14.93 million for the quarter ending September 30, 2023, a +14.64% increase year-over-year.
Zomedica Corp (ZOM) Cash Flow 2023
ZOM recorded a free cash flow (TTM) of -$25.79 million for the quarter ending September 30, 2023, a -57.53% decrease year-over-year.
Zomedica Corp (ZOM) Earnings per Share 2023
ZOM earnings per share (TTM) was -$0.019 for the quarter ending September 30, 2023, a -35.71% decline year-over-year.
About Zomedica Corp
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Cap:
|
Volume (24h):